Answers are grounded in this paper and cite their sources.
Introduction: Chronic lymphocytic leukemia (CLL) is one of the most common leukemia in adults and elderly worldwide. It is a heterogeneous disease with variable clinical pattern and evolution. It is characterized by the clonal expansion and accumulation of neoplastic B lymphocytes expressing CD5, CD19, CD20 and CD23 in the bone marrow, peripheral blood and often the lymph nodes. Aim of the work: Assessment of expression of IL-22 in patients with chronic lymphocytic leukemia. Study expression of CD38 in patients with chronic lymphocytic leukemia. Correlate both parameters with each other and with clinical and laboratory data studied. Subjects and Methods: The present study was carried out at Clinical Pathology Department, Faculty of Medicine, Minia University. It was conducted on thirty five newly diagnosed B-CLL patients and thirty five apparently healthy individuals as control. Results: The present study included seventy subjects; thirty five newly diagnosed B-CLL patients and thirty five apparently healthy individuals as control. The patients were selected from Minia University Hospital Outpatient Oncology clinic and Minia Oncology Center from March 2018 to November 2018. Summary: This study was carried out at Clinical Pathology Department, Faculty of Medicine, Minia University.
No takes yet. Share an insight, caveat, or question.
Al-Sharkawy et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: